CompanyHealth
AltruBio Inc.
AltruBio is a clinical-stage San Francisco biotech developing first-in-class immune checkpoint enhancer antibodies for autoimmune and inflammatory diseases. Its lead program, ALTB-268, targets PSGL-1 to restore T-cell homeostasis, and is advancing through mid-stage trials in ulcerative colitis. The company rebranded from AbGenomics in 2020 under CEO Judy Chou and closed an oversubscribed $225M Series B in 2024.
2006Founded
San FranciscoHQ
~$327.7MTotal funding to date
biotechimmunologyautoimmuneclinical-stageulcerative-colitispsgl-1